The company said it will continue with its plan to file data from the trial with the FDA, soothing some investor concerns.

Bexson Biomedical

The biopharmaceutical company is testing with multiple U.S. military branches at Northern Strike to provide Bexson’s BB106 ketamine therapy for pain management for contested environments.

Roche

Amid the impending drug pricing pressures from the Inflation Reduction Act, Roche is discontinuing a mid-stage hemophilia A gene therapy candidate and four other early-stage hopefuls.

liver tumors

Late-stage data, which showed significant overall and progression-free survival benefits in unresectable hepatocellular carcinoma patients, supports Elevar’s New Drug Application filed in May 2023.

Despite the lifting of the FDA’s partial clinical hold, Gilead will discontinue magrolimab’s development in higher-risk myelodysplastic syndromes after a Phase III study met the bar for futility.

The decision comes after the company failed to improve vision in two late-stage studies testing its drug against diabetic macular edema.

Doctor examines patient's neck

While six of the fatalities were deemed “unlikely or unrelated to the study drug,” the company nevertheless elected to suspend the entry of patients into the study.

Flu vaccine

Even at its highest dose, Vir Biotechnology’s investigational flu shot failed to significantly outperform placebo at preventing influenza A illness in a mid-stage study.

clinical research

The program—a joint initiative between CDER and CBER—aims to accelerate the development of therapies for rare diseases.

GSK

GSK has licensed out its Shigella vaccine candidate to LimmaTech Biologics, giving the Swiss biotech rights to further develop and eventually commercialize the quadrivalent bioconjugate investigational vaccine, the companies announced.